Plain-English translation of NCT07439653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is a Phase 1/2 trial testing a new medication called for people with B-cell non-Hodgkin lymphoma that has returned after treatment or stopped responding to standard therapies. The study will first figure out the safest and most effective dose of the medication given alone, then test it combined with another drug. Researchers want to understand how well this treatment works and what side effects people experience.
Many people with relapsed or refractory lymphoma run out of effective treatment options, and their lymphoma continues to grow despite standard therapies. This trial exists to see whether this new medication can offer hope to patients who need new treatment approaches.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an infusion or injection once every three weeks at a clinic or hospital. Depending on which part of the trial you join, you might receive the medication alone or combined with another treatment. You'll have regular visits for blood work, imaging scans, and check-ups to monitor how well the treatment is working and watch for side effects. The trial involves multiple visits over several months, with the exact timeline depending on how your cancer responds.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States